Different Gap Junction-propagated Effects on Cisplatin Transfer Result in Opposite Responses to Cisplatin in Normal Cells Versus Tumor Cells

Overview

Journal Sci Rep

Specialty Science

Date 2015 Jul 29

PMID 26215139

Citations 13

Authors

Yuan Zhang

Liang Tao

Lixia Fan

Yuexia Peng

Kefan Yang

Yifan Zhao

Qi Song

Qin Wang

Affiliations

Soon will be listed here.

Abstract

Previous work has shown that gap junction intercellular communication (GJIC) enhances cisplatin (Pt) toxicity in testicular tumor cells but decreases it in non-tumor testicular cells. In this study, these different GJIC-propagated effects were demonstrated in tumor versus non-tumor cells from other organ tissues (liver and lung). The downregulation of GJIC by several different manipulations (no cell contact, pharmacological inhibition, and siRNA suppression) decreased Pt toxicity in tumor cells but enhanced it in non-tumor cells. The in vivo results using xenograft tumor models were consistent with those from the above-mentioned cells. To better understand the mechanism(s) involved, we studied the effects of GJIC on Pt accumulation in tumor and non-tumor cells from the liver and lung. The intracellular Pt and DNA-Pt adduct contents clearly increased in non-tumor cells but decreased in tumor cells when GJIC was downregulated. Further analysis indicated that the opposite effects of GJIC on Pt accumulation in normal versus tumor cells from the liver were due to its different effects on copper transporter1 and multidrug resistance-associated protein2, membrane transporters attributed to intracellular Pt transfer. Thus, GJIC protects normal organs from cisplatin toxicity while enhancing it in tumor cells via its different effects on intracellular Pt transfer.

Citing Articles

Connexin-Containing Vesicles for Drug Delivery.

Hanafy M, Cui Z AAPS J. 2024; 26(1):20.

PMID: 38267725 DOI: 10.1208/s12248-024-00889-8.

Supporting Cells and Their Potential Roles in Cisplatin-Induced Ototoxicity.

Waissbluth S, Maass J, Sanchez H, Martinez A Front Neurosci. 2022; 16:867034.

PMID: 35573297 PMC: 9104564. DOI: 10.3389/fnins.2022.867034.

Citrus Flavone Tangeretin Inhibits CRPC Cell Proliferation by Regulating Cx26, AKT, and AR Signaling.

Zhang N, Wu W, Huang Y, An L, He Z, Chang Z Evid Based Complement Alternat Med. 2022; 2022:6422500.

PMID: 35111229 PMC: 8803427. DOI: 10.1155/2022/6422500.

Gap Junction Liposomes for Efficient Delivery of Chemotherapeutics to Solid Tumors.

Trementozzi A, Hufnagel S, Xu H, Hanafy M, Rosero Castro F, Smyth H ACS Biomater Sci Eng. 2021; 6(9):4851-4857.

PMID: 33455217 PMC: 8483596. DOI: 10.1021/acsbiomaterials.0c01047.

Nitric oxide affects cisplatin cytotoxicity oppositely in A2780 and A2780-CDDP cells via the connexin32/gap junction.

Fan L, Zheng N, Peng F, Zhao Z, Fan D, Cai S Cancer Sci. 2020; 111(8):2779-2788.

PMID: 32342615 PMC: 7419057. DOI: 10.1111/cas.14436.

References

Tao L, Harris A . 2-aminoethoxydiphenyl borate directly inhibits channels composed of connexin26 and/or connexin32. Mol Pharmacol. 2006; 71(2):570-9. DOI: 10.1124/mol.106.027508. View

Jensen R, Glazer P . Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proc Natl Acad Sci U S A. 2004; 101(16):6134-9. PMC: 395935. DOI: 10.1073/pnas.0400051101. View

Wen X, Buckley B, McCandlish E, Goedken M, Syed S, Pelis R . Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am J Pathol. 2014; 184(5):1299-308. PMC: 4005989. DOI: 10.1016/j.ajpath.2014.01.025. View

Holzer A, Manorek G, Howell S . Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006; 70(4):1390-4. DOI: 10.1124/mol.106.022624. View

Cronier L, Crespin S, Strale P, Defamie N, Mesnil M . Gap junctions and cancer: new functions for an old story. Antioxid Redox Signal. 2008; 11(2):323-38. DOI: 10.1089/ars.2008.2153. View

Ishida S, McCormick F, Smith-McCune K, Hanahan D . Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell. 2010; 17(6):574-83. PMC: 2902369. DOI: 10.1016/j.ccr.2010.04.011. View

Leithe E, Sirnes S, Omori Y, Rivedal E . Downregulation of gap junctions in cancer cells. Crit Rev Oncog. 2007; 12(3-4):225-56. DOI: 10.1615/critrevoncog.v12.i3-4.30. View

Mancuso M, Pasquali E, Leonardi S, Rebessi S, Tanori M, Giardullo P . Role of connexin43 and ATP in long-range bystander radiation damage and oncogenesis in vivo. Oncogene. 2011; 30(45):4601-8. DOI: 10.1038/onc.2011.176. View

Naus C, Laird D . Implications and challenges of connexin connections to cancer. Nat Rev Cancer. 2010; 10(6):435-41. DOI: 10.1038/nrc2841. View

10.

Hall M, Okabe M, Shen D, Liang X, Gottesman M . The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2007; 48:495-535. DOI: 10.1146/annurev.pharmtox.48.080907.180426. View

11.

Vinken M, Vanhaecke T, Papeleu P, Snykers S, Henkens T, Rogiers V . Connexins and their channels in cell growth and cell death. Cell Signal. 2005; 18(5):592-600. DOI: 10.1016/j.cellsig.2005.08.012. View

12.

Goldberg G, Bechberger J, Naus C . A pre-loading method of evaluating gap junctional communication by fluorescent dye transfer. Biotechniques. 1995; 18(3):490-7. View

13.

Holzer A, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R . The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004; 66(4):817-23. DOI: 10.1124/mol.104.001198. View

14.

Ciarimboli G . Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol. 2011; 7(2):159-74. DOI: 10.1517/17425255.2011.547474. View

15.

Kandouz M, Batist G . Gap junctions and connexins as therapeutic targets in cancer. Expert Opin Ther Targets. 2010; 14(7):681-92. DOI: 10.1517/14728222.2010.487866. View

16.

Patel S, Milwid J, King K, Bohr S, Iracheta-Vellve A, Iracheta-Velle A . Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol. 2012; 30(2):179-83. PMC: 3609650. DOI: 10.1038/nbt.2089. View

17.

Guminski A, Balleine R, Chiew Y, Webster L, Tapner M, Farrell G . MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol. 2005; 100(2):239-46. DOI: 10.1016/j.ygyno.2005.08.046. View

18.

Palipoch S, Punsawad C . Biochemical and histological study of rat liver and kidney injury induced by Cisplatin. J Toxicol Pathol. 2013; 26(3):293-9. PMC: 3787607. DOI: 10.1293/tox.26.293. View

19.

Czyz J . The stage-specific function of gap junctions during tumourigenesis. Cell Mol Biol Lett. 2007; 13(1):92-102. PMC: 6275873. DOI: 10.2478/s11658-007-0039-5. View

20.

Klee P, Allagnat F, Pontes H, Cederroth M, Charollais A, Caille D . Connexins protect mouse pancreatic β cells against apoptosis. J Clin Invest. 2011; 121(12):4870-9. PMC: 3225984. DOI: 10.1172/JCI40509. View